Intraocular pressure reduction in neovascular glaucoma using Ex-PRESS implantation

Document Type : Original Article

Authors

1 Department of Ophthalmology, Faculty of Medicine, Sohag University.

2 Department of Ophthalmology, Faculty of Medicine, Sohag University

Abstract

Purpose: evaluation of the role of the Ex-PRESS device implantation in IOP reduction of neovascular glaucoma.
Design: non-comparative case series study.
Patients and methods: 5 eyes with neovascular glaucoma scheduled to undergo Ex-PRESS glaucoma filtration device. Each study patient underwent a complete ophthalmic examination preoperatively including full clinical history taking, VA measurement, autorefraction examination, slit lamp biomicroscopy of the anterior segment, IOP measurement using Goldmann applanation tonometer, gonioscopic examination to evaluate of the angle of AC, and ophthalmoscopy of the posterior segment using a direct ophthalmoscopy. All patients included were having neovascular OAG (angle grade 3 and 4 on Shaffer classification). Patients were excluded if they were under 18 years old. All eyes underwent Ex-PRESS device implantation performed by the same surgeon for consistency, using the standardized technique for the procedure. A complete ophthalmologic follow-up examination included IOP measurement using Goldmann applanation tonometry, number of drugs required to attain IOP control and any associated complications was carried out postoperatively at the 1st and 3rd days, the end of 1st week, every month till the end of the 6th month and the end of 1st year. Best-corrected visual acuity (BCVA) was tested using Snellen chart, which was converted to LogMAR for statistical analysis. Criteria for success were defined as follows; Absolute success: IOP ≤21 mmHg without any medication, qualified success: IOP ≤21 mmHg with ocular hypotensive medications.
Results: all cases (100%) showed qualified success. There is a statistically significant reduction in IOP 1, 3, 6 months and one year postoperatively (P<0.001) with the most reduction in IOP observed at 6 months after surgery due to controlling all cases with IOP >21 mmHg using anti-glaucoma medications by this time. There is a statistically significant improvement of postoperative BCVA (P=0.002). Moreover, there is a statistically significant reduction of number of anti-glaucoma medications used postoperatively (P<0.001).
Conclusion: Ex-PRESS is preferable for neovascular glaucoma.
 

References

  1. Gan L, Fagerholm P and Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557-63.
  2. Olmos LC and Lee RK. Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin. 2011;51(3): 27-36.
  3. Park UC, Park KH, Kim DM, et al. Ahmed glaucoma valve implantation for neovascular glaucoma after vitrectomy for proliferative diabetic retinopathy. J Glaucoma. 2011;20(7):433-8.
  4. Francis BA, Singh K, Lin SC, et al. Novel glaucoma procedures: a report by the American Academy of Ophthalmology. Ophthalmol. 2011;118(7):1466-80.
  5. Grewal DS, Jain R, Kumar H, et al. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study. Ophthalmol. 2008;115(12):2141-5.
  6. Nilforushan N, Yadgari M, Kish SK, et al. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012;153(2):352-7.e1.
  7. Jonas JB, Spandau UH and Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res. 2007;39(2):121-2.
  8. Quigley HA and Broman AT. The number of people of glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7.
  9. Netland PA, Sarkisian SR Jr, Moster MR, et al. Randomized, prospec‌tive, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). Am J Ophthalmol. 2014;157(2):433-40.e3.
  10. Wang W, Zhou M, Huang W, et al. Ex-PRESS implantation versus trabeculectomy in uncontrolled glaucoma: A meta-analysis. PLoS One. 2013;8:e63591.
  11. Yu TC, Tseng GL, Chen CC, et al. Surgical treatment of neovascular glaucoma with Ex-PRESS glaucoma shunt: Case report. Medicine. 2017;96:(35):e7845.
  12. Takihara Y, Inatani M, Kawaji T, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma. 2011;20:196-201.
  13. Choi MY and Hyung SM. Effect of postoperative mitomycin C eyedrop on trabeculectomy in refractory glaucoma patients. Korean J Ophthalmol. 1996;10:34-41.
  14. Arcieri ES, Paula JS, Jorge R, et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmol. 2015;93:e1-6.
  15. Kim TW, Lindsey JD, Aihara M, et al. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest Ophthalmol Vis Sci. 2002;43:1809-16.
  16. Kim MJ, Han ES, Kim J, et al. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit. J Ocul Pharmacol Ther. 2010;26:49-53.
  17. Mizote M, Baba T, Hirooka K, et al. Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma. Jpn J Ophthalmol. 2010;54:242-4.
  18. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50:5217-25.
  19. Park H, Kim J, Ahn M, et al. Level of vascular endothelial growth factor in tenon tissue and results of glaucoma surgery. Arch Ophthalmol. 2012;130:685-9.
  20. Kim M, Lee C, Payne R, et al. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: a review. Surv Ophthalmol. 2015;60:524-35.
  21. Liu JH,  Lin HY,  Tzeng SH, et al. Comparison of trabeculectomy with Ex-PRESS shunt implantation in primary-open-angle-glaucoma patients: A retrospective study. Taiwan J Ophthalmol. 2015;5(3):120-3.
  22. Bustros YD, Fechtner R and Khouri AS. Outcomes of Ex-PRESS and trabeculectomy in a glaucoma population of African origin: one year results. J Curr Glaucoma Pract. 2017;11(2):42-7.
  23. Good TJ and Kahook MY. Assessment of bleb morphologic features and postoperative outcomes after Ex-PRESS drainage device implantation versus trabeculectomy. Am J Ophthalmol. 2011;151:507-13.e1.
  24. Costa VP, Smith M, Spaeth GL, et al. Loss of visual acuity after trabeculectomy. Ophthalmol. 1993;100:599-612.
  25. Levene RZ. Central visual field, visual acuity, and sudden visual loss after glaucoma surgery. Ophthalmic Surg. 1992;23:388-94.
  26. Wagschal LD, Trope GE, Jinapriya D, et al. Prospective randomized study comparing Ex-PRESS to trabeculectomy: 1-year results. J Glaucoma. 2015;24(8):624-9.
  27. Beltran-Agullo L, Trope GE, Jin Y, et al. Comparison of visual recovery following Ex-PRESS versus trabeculec‌tomy: results of a prospective randomized controlled trial. J Glaucoma. 2015;24:181-6.                                                                                                                

Sohag Medical Journal
Volume 22, Issue 3
October 2018
Pages 201-208

Files

Share

How to cite

Statistics